Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD‐19 chimeric antigen receptor T‐cell therapy
oleh: Francesco Paolo Tambaro, Sajad Khazal, Cesar Nunez, Dristhi Ragoonanan, Priti Tewari, Demetrios Petropoulos, Partow Kebriaei, William George Wierda, Kris Michael Mahadeo
| Format: | Article |
|---|---|
| Diterbitkan: | Wiley 2020-09-01 |
Deskripsi
Abstract The T‐cell engager monoclonal antibody, blinatumomab, is a potential therapeutic strategy for refractory B acute lymphoblastic leukemia after failure of CD 19 chimeric antigen receptor T‐cell therapy.